The Oncology Institute, Inc. TOI Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

McKessonMCK

——

Option Care Health, Inc.OPCH

——

Jazz PharmaceuticalsJAZZ

——

Inhibrx Biosciences, Inc.INBX

——

Privia Health Group, Inc.PRVA

——

Other financials

Income statement

See full

Revenue$147.4M+41.2%

Operating income-$6.5M+34.3%

Net income-$2.5M+87.3%

EPS (diluted)-$0.02+90.5%

Balance sheet

See full

Cash & equivalents$30.3M-23.8%

Total debt$104.9M+2.5%

Total equity-$16.3M-421%

Total assets$168.2M+2.6%

Cash flow

See full

Operating cash flow-$2.2M+55.6%

CapEx$1.0M+218%

Free cash flow-$3.3M+38.7%

Valuation

See full

Market cap$511.91M+133%

Enterprise value$586.58M+108%

P/S0.9×+0.4×

Profitability

See full

Operating margin-6%-2.1pp

Net margin-8%-2.7pp

FCF margin-5.1%—

Returns & leverage

See full

Return on equity-277.6%-700pp

Debt / equity20.2×+17.3×

Current ratio1.5×-0.3×

Where this comes from

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is The Oncology Institute, Inc.'s remainder of fiscal year 2024?: The Oncology Institute, Inc. (TOI) reported remainder of fiscal year 2024 of $0 in Q1 2026.